Technical Analysis for BIVV - Bioverativ Inc

Grade Last Price % Change Price Change
grade A 104.98 0.32% 0.33
BIVV closed up 0.32 percent on Thursday, March 8, 2018, on 28 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Very Strong Up Up Flat
See historical BIVV trend table...

Date Alert Name Type % Chg
Jan 23 Slingshot Bullish Bullish Swing Setup 1.76%
Jan 23 Volume Surge Other 1.76%
Jan 23 Calm After Storm Range Contraction 1.76%
Jan 23 Narrow Range Bar Range Contraction 1.76%
Jan 23 NR7 Range Contraction 1.76%
Jan 23 NR7-2 Range Contraction 1.76%
Jan 23 Upper Bollinger Band Walk Strength 1.76%
Jan 23 Wide Bands Range Expansion 1.76%
Jan 23 Above Upper BB Strength 1.76%
Jan 23 Overbought Stochastic Strength 1.76%

Older signals for BIVV ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Bioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person's blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN).
Is BIVV a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 105.01
52 Week Low 48.14
Average Volume 2,837,550
200-Day Moving Average 64.8138
50-Day Moving Average 88.3632
20-Day Moving Average 104.181
10-Day Moving Average 104.744
Average True Range 0.7932
ADX 69.93
+DI 49.41
-DI 11.97
Chandelier Exit (Long, 3 ATRs ) 102.6304
Chandelier Exit (Short, 3 ATRs ) 104.8896
Upper Bollinger Band 105.4138
Lower Bollinger Band 102.9482
Percent B (%b) 0.82
BandWidth 2.36665
MACD Line 3.7955
MACD Signal Line 5.0337
MACD Histogram -1.2383
Fundamentals Value
Market Cap 11.36 Billion
Num Shares 108 Million
EPS 4.21
Price-to-Earnings (P/E) Ratio 24.94
Price-to-Sales 5.99
Price-to-Book 9.21
PEG Ratio 1.31
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 105.04
Resistance 3 (R3) 105.04 105.03 105.03
Resistance 2 (R2) 105.03 105.01 105.03 105.03
Resistance 1 (R1) 105.00 105.00 105.02 105.00 105.02
Pivot Point 104.99 104.99 104.99 104.99 104.99
Support 1 (S1) 104.96 104.97 104.98 104.96 104.94
Support 2 (S2) 104.95 104.96 104.95 104.93
Support 3 (S3) 104.92 104.95 104.93
Support 4 (S4) 104.92